CFO exit at Kalaris Therapeutics (NASDAQ: KLRS) as Brett Hagen takes finance lead

Rhea-AI Filing Summary

Kalaris Therapeutics, Inc. announced that Chief Financial Officer Matthew Gall will resign effective April 14, 2026. In connection with his departure, Brett Hagen, the current Chief Accounting Officer and principal accounting officer, will also serve as the company’s principal financial officer from the same date.

The filing outlines Mr. Hagen’s prior senior finance roles at several biopharmaceutical companies and his academic background in accounting and finance. It also notes that he has no family relationships with directors or officers, no related-party transactions requiring disclosure, and that his compensation arrangements remain unchanged.

Insights

Corporate governance analyst

CFO exit with internal succession; continuity but added key-person risk.

Kalaris Therapeutics reports the resignation of CFO Matthew Gall effective April 14, 2026, while elevating Chief Accounting Officer Brett Hagen to also serve as principal financial officer. This is an internal succession, which generally supports operational continuity in finance and reporting.

The filing emphasizes Mr. Hagen’s prior senior roles at other therapeutics companies and confirms no related-party conflicts or new compensation changes. The transition concentrates financial leadership responsibilities in one executive, so future disclosures will show how effectively this dual role supports controls, reporting quality, and capital markets interactions.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

CFO separation date: April 14, 2026 Age of new principal financial officer: 53 years Chief Accounting Officer tenure start: January 2019

3 metrics

CFO separation date April 14, 2026 Effective date of Matthew Gall’s resignation as CFO

Age of new principal financial officer 53 years Age of Chief Accounting Officer and principal financial officer Brett Hagen

Chief Accounting Officer tenure start January 2019 Start of Brett Hagen’s role as Chief Accounting Officer

Key Terms

Emerging growth company, principal financial officer, principal accounting officer, Item 404(a) of Regulation S-K

4 terms

Emerging growth company regulatory

"Emerging growth company    Resignation of Chief Financial Officer"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

principal financial officer financial

"will also serve as the Company’s principal financial officer, effective as of the Separation Date"

The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.

principal accounting officer financial

"the Company’s Chief Accounting Officer and principal accounting officer, will also serve"

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

Item 404(a) of Regulation S-K regulatory

"no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K"

Understanding 8-K Material Events →

false 0001754068 0001754068 2026-04-08 2026-04-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 8, 2026

KALARIS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39409		83-1971007
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Kalaris Therapeutics, Inc.

400 Connell Drive, Suite 5500

Berkeley Heights, New Jersey 07922

(Address of principal executive offices, including zip code)

(650) 249-2727

(Registrant’s telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		KLRS		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Chief Financial Officer

On April 8, 2026, Matthew Gall notified Kalaris Therapeutics, Inc. (the “Company”) of his decision to resign as the Chief Financial Officer of the Company, effective April 14, 2026 (the “Separation Date”).

Appointment of Principal Financial Officer

As a result of Mr. Gall’s resignation, Brett Hagen, the Company’s Chief Accounting Officer and principal accounting officer, will also serve as the Company’s principal financial officer, effective as of the Separation Date.

Brett Hagen, 53, has served as the Company’s Chief Accounting Officer since January 2019. Prior to joining the Company, Mr. Hagen served as senior director finance and accounting at Eloxx Pharmaceuticals, Inc. from February 2018 to August 2018. Prior to that, Mr. Hagen served as vice president, finance and controller at Proteostasis Therapeutics, Inc. from May 2016 to December 2017. From July 2014 to May 2016, Mr. Hagen served as controller at BIND Therapeutics, Inc. Mr. Hagen received his B.A. from the University of Minnesota, a graduate degree in accounting from Wright State University and a graduate degree in finance from Suffolk University.

Mr. Hagen does not have a family relationship with any of the Company’s officers or directors and has no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

There have been no changes to Mr. Hagen’s compensatory plans or arrangements in connection with his appointment described herein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				KALARIS THERAPEUTICS, INC.
Date: April 10, 2026				By:		/s/ Andrew Oxtoby
				Name:		Andrew Oxtoby
				Title:		Chief Executive Officer

FAQ

Why did Kalaris Therapeutics (KLRS) file this 8-K on April 8, 2026?

The 8-K reports leadership changes in Kalaris Therapeutics’ finance function. Chief Financial Officer Matthew Gall decided to resign effective April 14, 2026, and the company designated Chief Accounting Officer Brett Hagen to also serve as principal financial officer starting on the same date.

When is Kalaris Therapeutics (KLRS) CFO Matthew Gall’s resignation effective?

Matthew Gall’s resignation as Chief Financial Officer becomes effective on April 14, 2026. Until that separation date, he remains in the role. After that date, Kalaris will rely on Chief Accounting Officer Brett Hagen as its designated principal financial officer.

Who will serve as principal financial officer at Kalaris Therapeutics (KLRS) after April 14, 2026?

After April 14, 2026, Chief Accounting Officer Brett Hagen will also serve as Kalaris Therapeutics’ principal financial officer. He has held the Chief Accounting Officer role since January 2019 and previously worked in senior finance positions at several biopharmaceutical companies.

Did Kalaris Therapeutics (KLRS) change Brett Hagen’s compensation with this new role?

No, the company states there were no changes to Mr. Hagen’s compensatory plans or arrangements in connection with his appointment as principal financial officer. His existing compensation structure continues alongside his expanded responsibilities.

Does Kalaris Therapeutics (KLRS) disclose any related-party conflicts for new principal financial officer Brett Hagen?

The filing notes that Brett Hagen has no family relationship with any of the company’s officers or directors and no direct or indirect interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.

What is Brett Hagen’s background before becoming principal financial officer at Kalaris Therapeutics (KLRS)?

Brett Hagen, age 53, has been Chief Accounting Officer since January 2019 and previously held senior finance roles at Eloxx Pharmaceuticals, Proteostasis Therapeutics, and BIND Therapeutics. He holds a B.A. and graduate degrees in accounting and finance from multiple universities.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB